微量白蛋白尿

维基百科,自由的百科全书
跳转至: 导航搜索
微量白蛋白尿
(Microalbuminuria)
ICD-9 791.0
MedlinePlus 003591

微量白蛋白尿(microalbuminuria)是用來描述白蛋白尿水平適度增加的醫學術語。它發生在洩漏少量白蛋白(Human serum albumin)進入尿液裡、換言之,即在腎臟腎小球的白蛋白有異常高的滲透性(Vascular permeability)。這個醫學術語"微量白蛋白尿"現在KDIGO(Kidney Disease Improving Global Outcomes/腎臟病改善全球成果)計劃不建議使用,並以"中度增加白蛋白尿"取代之。

病因[编辑]

  • 血管內皮功能障礙(endothelial dysfunction)的標誌。
  • 腎臟疾病預後的重要標誌:

診斷[编辑]

微量白蛋白尿定義
個人 底限 高限 單位
24小時尿液收集 30[1] 300[1] mg/24h (每24小時的毫克白蛋白)
短時間尿液收集 20[1] 200[1] µg/min (每分鐘的微克白蛋白)
定點白蛋白尿樣本 30[2] 300[2] mg/L (每公升尿液的毫克白蛋白)
定點白蛋白尿/肌酸酐比值 女人 3.5[3] 25[3] or 35[3] mg/mmol (每摩爾肌酸酐的毫克白蛋白)
30[3] 400[3] μg/mg (每毫克肌酸酐的毫克白蛋白)
男人 2.5[3] or 3.5[3] 25[3] or 35[3] mg/mmol
30[3] 300[3] μg/mg

參見[编辑]

註釋[编辑]

  1. ^ 1.0 1.1 1.2 1.3 Page 90 in: Basic Skills in Interpreting Laboratory Data. ISBN 978-1-58528-180-0 
  2. ^ 2.0 2.1 Person—microalbumin level (measured) at Australian Institute of Health and Welfare. 01/03/2005
  3. ^ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 [1] Justesen, T.; Petersen, J.; Ekbom, P.; Damm, P.; Mathiesen, E. Albumin-to-creatinine ratio in random urine samples might replace 24-h urine collections in screening for micro- and macroalbuminuria in pregnant woman with type 1 diabetes. Diabetes Care. 2006, 29 (4): 924–925. PMID 16567839. doi:10.2337/diacare.29.04.06.dc06-1555.  编辑

參考文獻[编辑]

  • Abid O, Sun Q, Sugimoto K, Mercan D, Vincent JL. Predictive value of microalbuminuria in medical ICU patients: results of a pilot study. Chest. 2001, 120 (6): 1984–8. PMID 11742932. doi:10.1378/chest.120.6.1984. 
  • Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int. 2000, 58 (5): 2129–37. PMID 11044234. doi:10.1111/j.1523-1755.2000.00386.x. 
  • Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000, 355 (9200): 253–9. PMID 10675071. doi:10.1016/S0140-6736(99)12323-7. 
  • Lemley KV; Abdullah I; Myers BD; 等. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int. 2000, 58 (3): 1228–37. PMID 10972685. doi:10.1046/j.1523-1755.2000.00223.x. 
  • Lièvre M; Marre M; Chatellier G; 等. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group. Controlled Clinical Trials. 2000, 21 (4): 383–96. PMID 10913814. doi:10.1016/S0197-2456(00)00060-X. 
  • Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001, 345 (12): 870–8. PMID 11565519. doi:10.1056/NEJMoa011489. 
  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 1-150.

外部連結[编辑]